(19)
(11) EP 1 471 926 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.09.2011 Bulletin 2011/38

(45) Mention of the grant of the patent:
08.12.2010 Bulletin 2010/49

(21) Application number: 00941220.6

(22) Date of filing: 01.06.2000
(51) International Patent Classification (IPC): 
A61K 38/00(2006.01)
(86) International application number:
PCT/US2000/015410
(87) International publication number:
WO 2000/073764 (07.12.2000 Gazette 2000/49)

(54)

COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF AN ATONAL-ASSOCIATED SEQUENCE

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR THERAPEUTISCHEN ANWENDUNG EINER MIT DEM GEN ATONAL ASSOZIIERTEN SEQUENZ

COMPOSITIONS ET METHODES POUR L'UTILISATION THERAPEUTIQUE D'UNE SEQUENCE ASSOCIEE AU GENE ATONAL

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 01.06.1999 US 137060 P
19.01.2000 US 176993 P

(43) Date of publication of application:
03.11.2004 Bulletin 2004/45

(60) Divisional application:
10010154.2 / 2325198

(73) Proprietor: BAYLOR COLLEGE OF MEDICINE
Houston, TX 77030 (US)

(72) Inventors:
  • ZOGHBI, Huda, Y.
    Houston, TX 77005 (US)
  • BELLEN, Hugo
    Houston, TX 77006 (US)
  • BERMINGHAM, Nessan
    Boston MA 02116 (US)
  • HASSAN, Bassem
    Houston, TX 77006 (US)
  • BEN-ARIE, Nissim, Dept. of Cell and Animal Biology
    91904 Jerusalem (IL)

(74) Representative: Woods, Geoffrey Corlett 
J.A. Kemp & Co. 14 South Square
Gray's Inn London WC1R 5JJ
Gray's Inn London WC1R 5JJ (GB)


(56) References cited: : 
   
  • BEN-ARIE N. ET AL.: 'Abnormal cerebellar development in mice lacking the murine homolog of the drosophila proneural gene atonal' AMERICAN J. HUMAN GENETICS vol. 59, no. 4, SUPPL., 1996, page A46, ABSTRACT NO. 232, XP002934142
  • BEN-ARIE N. ET AL.: 'Math1 is essential for genesis of cerebellar granule neurons' NATURE vol. 390, 13 November 1997, pages 169 - 172, XP002934141
  • SUN Y. ET AL.: 'Transcriptional regulation of atonal during development of the drosophila peripheral nervous system' DEVELOPMENT vol. 125, 1998, pages 3731 - 3740, XP002934140
  • SABATE O. ET AL.: 'Adenovirus for neurodegenerative diseases: In vivo strategies and ex vivo gene therapy using human neural progenitors' CLINICAL NEUROSCIENCE vol. 3, 1996, pages 317 - 321, XP002934139
  • WILLIAMS D.P. ET AL.: 'Structure/function analysis of interleukin-2-toxin (DAB486-IL-2), fragment B sequences required for the delivery of fragment A to the cytosol of target cells' J. BIOL. CHEM. vol. 265, no. 20, 15 July 1990, pages 11885 - 11887, XP002934138
  • CHIEN C.-T. ET AL.: 'Neuronal type information encoded in the basic-helix-loop-helix domain of proneural genes' PROC. NATL. ACAD. SCI. USA vol. 93, November 1996, pages 13239 - 13244, XP002934137
  • SCHWARZE S.R. ET AL.: 'In vivo protein transduction: delivery of a biologically active protein into the mouse' SCIENCE vol. 285, 03 September 1999, pages 1569 - 1572, XP002934136
  • VERMA I.M. ET AL.: 'Gene therapy-promises, problems and prospects' NATURE vol. 389, 18 September 1997, pages 239 - 242, XP002934135
  • LEDLEY F.D.: 'Pharmaceutical approach to somatic gene therapy' PHARMACEUTICAL RESEARCH vol. 13, no. 11, November 1996, pages 1595 - 1614, XP002934134
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).